RESUMEN
It is unclear whether elderly patients established on direct oral anticoagulants (DOACs) have greater exposure to these drugs, which could subsequently increase their risk of bleeding. We assessed DOAC exposure and factors affecting it in a real-world elderly cohort of patients. For this, 151 medically stable hospital inpatients (76 established on apixaban, 61 on rivaroxaban, 14 on dabigatran) with a median [interquartile range (IQR)] age of 84 (78-89) years were recruited. Patients provided blood samples for measurement of peak and trough plasma DOAC concentrations. There was up to 48-fold and 13-fold variation in trough and peak plasma drug concentrations respectively. A significantly greater proportion of patients on apixaban had peak plasma drug concentrations within the reported ranges compared to those on either rivaroxaban or dabigatran (82·9% vs. 44·3% vs. 64·3% respectively; P < 0·001). A third of the variability in DOAC plasma concentrations was attributed to the influences of DOAC dosage, renal function and gender. To what extent the observed increases in DOAC exposure in the older patients is the cause of their increased risk of bleeding, which could potentially be ameliorated by dosing titration, requires further investigation.
Asunto(s)
Inhibidores del Factor Xa/uso terapéutico , Trombosis/tratamiento farmacológico , Factores de Edad , Anciano , Anciano de 80 o más Años , Dabigatrán/sangre , Dabigatrán/uso terapéutico , Monitoreo de Drogas , Inhibidores del Factor Xa/sangre , Femenino , Hospitalización , Humanos , Masculino , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridonas/sangre , Piridonas/uso terapéutico , Rivaroxabán/sangre , Rivaroxabán/uso terapéutico , Trombosis/prevención & controlRESUMEN
OBJECTIVE: To report a near-fatal poisoning after intentional injection of ricin from a castor bean (Ricinus communis) extract. CASE REPORT: A 21 year-old man self-injected â¼3 mL of a castor bean extract intramuscularly and subcutaneously in the left antecubital fossa. Upon admission to our ED (1 h post-exposure; day 1, D1) he was awake and alert, but complained of mild local pain and showed slight local edema and erythema. He evolved to refractory shock (â¼24 h post-exposure) that required the administration of a large volume of fluids and high doses of norepinephrine and vasopressin, mainly from D2 to D4. During this period, he developed clinical and laboratory features compatible with systemic inflammatory response syndrome, multiple organ dysfunction, capillary leak syndrome, rhabdomyolysis, necrotizing fasciitis and possible compartment syndrome. The patient underwent forearm fasciotomy on D4 and there was progressive improvement of the hemodynamic status from D7 onwards. Wound management involved several debridements, broad-spectrum antibiotics and two skin grafts. Major laboratory findings within 12 days post-exposure revealed hypoalbuminemia, proteinuria, thrombocytopenia, leukocytosis and increases in cytokines (IL-6, IL-10 and TNF-α), troponin and creatine kinase. Ricin A-chain (ELISA) was detected in serum up to D3 (peak at 24 h post-exposure), with â¼79% being excreted in the urine within 64 h post-exposure. Ricinine was detected in serum and urine by LC-MS up to D5. A ricin A-chain concentration of 246 µg/mL was found in the seed extract, corresponding to the injection of â¼738 µg of ricin A-chain (â¼10.5 µg/kg). The patient was discharged on D71, with limited range of motion and function of the left forearm and hand. CONCLUSION: Ricin injection resulted in a near-fatal poisoning that evolved with septic shock-like syndrome, multiple organ dysfunction and necrotizing fasciitis, all of which were successfully treated with supportive care.
Asunto(s)
Ricina/envenenamiento , Adulto , Alcaloides/sangre , Ricinus communis/envenenamiento , Citocinas/sangre , Humanos , Inyecciones , Masculino , Extractos Vegetales/envenenamiento , Piridonas/sangreRESUMEN
Approximately 1-2% of patients with non-valvular atrial fibrillation have an acute ischemic stroke (AIS) while on direct oral anticoagulant (DOAC) treatment every year. However, current evidence on stroke subtypes, pathophysiology and factors leading to the failure of DOAC preventive therapy in a "real world" setting is still scanty. This study aimed at investigating whether there is any relationship between DOAC plasma levels and the stroke occurrence, on the basis of the phenotypic classification and pathophysiology of the stroke, in a cohort of DOAC-treated patients admitted to our hospital for AIS over 1-year period. A total of 28 patients had DOAC plasma levels determined in emergency and were included in the study, nine patients receiving dabigatran, 11 rivaroxaban and 8 apixaban. The DOAC levels were low in 8/28 patients (28.6% of the sample), intermediate in 4 (14.3%) and high in 16 (57.1%). The most prevalent stroke subtype was the small vessel disease, according to the A-S-C-O phenotypic classification, in 53.6% of our sample. The most common clinical presentation was "minor stroke" in 71.4% of the cases. There was a significantly higher proportion of patients with high DOAC levels in the small vessel group, compared to the cardioembolic group without other phenotypes. The question arises as to the most suitable clinical management of AIS in these patients on DOACs. In the current absence of clear evidence, taking into account the DOAC levels (low/intermediate/high) and the underlying stroke pathophysiology, we present a flowchart of our proposed clinical management of ischemic stroke in patients while on DOAC.
Asunto(s)
Inhibidores del Factor Xa/sangre , Inhibidores del Factor Xa/uso terapéutico , Accidente Cerebrovascular Isquémico/etiología , Accidente Cerebrovascular Isquémico/prevención & control , Anciano , Anciano de 80 o más Años , Fibrilación Atrial/complicaciones , Dabigatrán/sangre , Dabigatrán/uso terapéutico , Manejo de la Enfermedad , Monitoreo de Drogas , Femenino , Humanos , Accidente Cerebrovascular Isquémico/sangre , Accidente Cerebrovascular Isquémico/fisiopatología , Italia/epidemiología , Masculino , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridonas/sangre , Piridonas/uso terapéutico , Estudios Retrospectivos , Rivaroxabán/sangre , Rivaroxabán/uso terapéuticoRESUMEN
PURPOSE: This study assessed the tolerability and pharmacokinetic (PK) properties of a new-generation oxazolidinone, contezolid (MRX-I), and its major inactive metabolite, M2, after single oral administrations of 800, 1200, and 1600 mg in the fed state, and compared the efficacy of 3 dosing regimens in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection based on PK/pharmacodynamic (PD) analysis. METHODS: A Phase I study at a single study center was conducted with 2 parts. In the first part, 20 healthy subjects received a single oral dose of 1200 or 1600 mg of contezolid or placebo in the fed state in a double-blind, placebo-controlled, dose-escalation tolerance study. In the second part of the study, 52 subjects received a single oral dose of 800 mg of contezolid in the fed state in a single-center, randomized, blinded, 4-period, crossover, thorough QT study. Noncompartmental analyses were used to evaluate the PK properties of contezolid and M2. Steady-state concentrations of contezolid following the 3 dosing regimens (800, 1200, and 1600 mg q12h) were simulated by employing a newly developed 2-compartmental PK model. The minimum inhibitory concentration (MIC) distributions of contezolid were analyzed in 178 Staphylococcus, Enterococcus, and Streptococcus clinical isolates. Monte Carlo simulations were conducted to predict the efficacy of the 3 dosing regimens to obtain probability of target attainment and cumulative fraction of response. FINDINGS: Single-dose oral administrations of 800, 1200, and 1600 mg of contezolid were well tolerated in healthy subjects in the fed state, and nonlinear PK was observed. The mean plasma exposures to M2 exceeded 17.3% of contezolid exposure in the 3 groups. Both MIC50 and MIC90 (MICs that inhibit the growth of 50% and 90% of microorganisms, respectively) of contezolid against MRSA were 1 mg/L with clinical isolates from China. PK/PD analysis and Monte Carlo simulations predicted that 800 mg q12h of oral contezolid would be efficacious against MRSA infection, with a MIC of ≤4 mg/L (probability of target attainment, >90%; cumulative fraction of response, >90%). IMPLICATIONS: Contezolid is a well-tolerated treatment option for MRSA infection, including at supratherapeutic doses up to 1600 mg. The regimen of 800 mg q12h could achieve efficacy in treating bacterial infection with MRSA. To our knowledge, this is the first PK study to predict that a dosing regimen of 800 mg q12h of oral contezolid is sufficient for treating MRSA infection, with a MIC of ≤4 mg/L. A Phase III study of this suggested dosing regimen is being conducted. Chinadrugtrials.org.cn identifier: CTR20161074.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Oxazolidinonas/administración & dosificación , Oxazolidinonas/farmacocinética , Piridonas/administración & dosificación , Piridonas/farmacocinética , Administración Oral , Antibacterianos/efectos adversos , Antibacterianos/sangre , Bacterias/efectos de los fármacos , Estudios Cruzados , Voluntarios Sanos , Humanos , Pruebas de Sensibilidad Microbiana , Oxazolidinonas/efectos adversos , Oxazolidinonas/sangre , Piridonas/efectos adversos , Piridonas/sangreRESUMEN
BACKGROUND: Apixaban and rivaroxaban are approved for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and embolic stroke in atrial fibrillation (AF) patients. The aim of this study was to find appropriate methods of monitoring the anticoagulant effects of are direct oral anticoagulants (DOACs) and establish on-therapy ranges using conventional tests. METHODS: A total of 184 samples were collected from 91 patients receiving DOACs. Concentrations of apixaban and rivaroxaban in plasma were accessed by an anti-factor Xa chromogenic assay. PT, APTT, antithrombin, D-dimer, dRVVT screen/confirm, FDP, and fibrinogen levels were measured. On-therapy ranges were calculated by substituting previously reported trough plasma concentrations of DOACs. RESULTS: Anti-factor Xa chromogenic assay-based DOACs levels were 26.0-279.5 (115.9 ± 56.5) ng/mL for apixaban at 2.5 mg BID, 19.9-565.1 (205.3 ± 162.4) ng/mL for apixaban at 5 mg BID, 2.3-395.3 (205.3 ± 162.4) ng/mL for rivaroxaban at 15 mg OD, 3.6-494.8 (119.6 ± 95.1) ng/mL for rivaroxaban at 20 mg OD, and 9.6-431.4 (140.8 ± 113.6) ng/mL for rivaroxaban at 15 mg BID. PT (%), antithrombin, and dRVVT confirm tests showed good correlation with plasma apixaban levels. Plasma rivaroxaban concentrations were correlated well with PT (sec), PT (%),and dRVVT confirm results. On-therapy ranges established for dRVVT confirm test by linear regression were as follows: 1.32-1.52 for apixaban 2.5 mg BID, 1.12-1.75 for apixaban 5 mg BID, 1.11-1.78 for rivaroxaban 15 mg OD, 1.09-1.64 for rivaroxaban 20 mg OD, and 1.22-1.81 for rivaroxaban 20 mg BID. CONCLUSIONS: Apixaban concentrations were well correlated with PT (%), antithrombin, and dRVVT confirm test. Rivaroxaban concentrations showed good correlation with PT (sec), PT (%), and dRVVT confirm test.
Asunto(s)
Pruebas de Coagulación Sanguínea/métodos , Inhibidores del Factor Xa/sangre , Pirazoles/sangre , Piridonas/sangre , Rivaroxabán/sangre , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Técnicas de Laboratorio Clínico , Inhibidores del Factor Xa/uso terapéutico , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Fibrinógeno/análisis , Humanos , Masculino , Persona de Mediana Edad , Tiempo de Protrombina , Pirazoles/uso terapéutico , Piridonas/uso terapéutico , Rivaroxabán/uso terapéutico , Venenos de VíborasRESUMEN
There is a high degree of uncertainty regarding optimum care of patients with potential or known intake of oral anticoagulants and traumatic brain injury (TBI). Anticoagulation therapy aggravates the risk of intracerebral hemorrhage but, on the other hand, patients take anticoagulants because of an underlying prothrombotic risk, and this could be increased following trauma. Treatment decisions must be taken with due consideration of both these risks. An interdisciplinary group of Austrian experts was convened to develop recommendations for best clinical practice. The aim was to provide pragmatic, clear, and easy-to-follow clinical guidance for coagulation management in adult patients with TBI and potential or known intake of platelet inhibitors, vitamin K antagonists, or non-vitamin K antagonist oral anticoagulants. Diagnosis, coagulation testing, and reversal of anticoagulation were considered as key steps upon presentation. Post-trauma management (prophylaxis for thromboembolism and resumption of long-term anticoagulation therapy) was also explored. The lack of robust evidence on which to base treatment recommendations highlights the need for randomized controlled trials in this setting.
Asunto(s)
Anticoagulantes/uso terapéutico , Lesiones Traumáticas del Encéfalo/tratamiento farmacológico , Administración Oral , Anticoagulantes/efectos adversos , Austria , Lesiones Traumáticas del Encéfalo/fisiopatología , Consenso , Dabigatrán/efectos adversos , Dabigatrán/uso terapéutico , Desamino Arginina Vasopresina/farmacología , Humanos , Comunicación Interdisciplinaria , Tiempo de Tromboplastina Parcial/métodos , Pirazoles/análisis , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridinas/análisis , Piridinas/sangre , Piridinas/uso terapéutico , Piridonas/análisis , Piridonas/sangre , Piridonas/uso terapéutico , Rivaroxabán/análisis , Rivaroxabán/sangre , Rivaroxabán/uso terapéutico , Tiazoles/análisis , Tiazoles/sangre , Tiazoles/uso terapéutico , Tromboembolia/prevención & control , Tomografía Computarizada por Rayos X/métodos , Ácido Tranexámico/uso terapéutico , Resultado del Tratamiento , Vitamina K/antagonistas & inhibidores , Vitamina K/uso terapéuticoRESUMEN
Ricin is a highly toxic agent derived from the castor bean plant (Ricinus communis). Poisoning occurs commonly by oral ingestion of the beans. Injection of ricin is believed to be more lethal. Ricin is a large glycosylated protein difficult to detect in clinical samples. Instead, ricinine, a small alkaloid found in the same beans, is used as surrogate marker for ricin exposure. We describe a simple LC-MS/MS method for the detection of ricinine in serum, blood and urine, validated according to EMA guidelines and successfully applied to patient samples of a suicidal death after injection of a castor bean extract. A 26-year-old man self-presented to the emergency department with severe abdominal cramps and nausea after injection of a castor bean extract. Due to rapid deterioration of his hemodynamic function despite early aggressive fluid resuscitation, he was transferred to ICU. Abdominal cramps worsened and a fulminant diarrhea developed, resulting in hypovolemic shock and cardiorespiratory collapse. Despite full supportive therapy, the patient died approximately 10 hours after injection due to multiple organ failure. Ricinine was quantified by LC-MS/MS after LLE with diethyl ether using ricinine-D3 as internal standard. Six hours after injection, ricinine concentrations in serum and blood were 16.5 and 12.9 ng/mL, respectively, which decreased to 12.4 and 10.6 ng/mL, 4 hours later. The urinary concentration was 81.1 ng/mL 7 hours after injection, which amply exceeded the levels previously reported in similar cases with lethal outcome. Concentrations of ricinine, compatible with a lethal exposure to castor beans, were detected in serum, blood and urine. Ricinine was also found in bile and liver tissue.
Asunto(s)
Alcaloides , Extractos Vegetales/envenenamiento , Piridonas , Ricinus/clasificación , Adulto , Alcaloides/sangre , Alcaloides/orina , Cromatografía Liquida , Cuidados Críticos , Resultado Fatal , Humanos , Inyecciones Intravenosas , Masculino , Extractos Vegetales/administración & dosificación , Intoxicación/sangre , Intoxicación/terapia , Intoxicación/orina , Piridonas/sangre , Piridonas/orina , Reproducibilidad de los Resultados , Intento de Suicidio , Espectrometría de Masas en TándemRESUMEN
There is limited clinical experience with the use of coagulation concentrates to reverse the effect of direct oral anticoagulants. We assess the achievement of effective clinical hemostasis with the use of 4-factor prothrombin complex concentrate (PCC) in patients on apixaban or rivaroxaban presenting with major bleeding. A retrospective chart review was conducted at a tertiary referral medical center in the USA. We assess the achievement of clinical hemostasis using 4-factor PCC in patients on chronic apixaban or rivaroxaban therapy presenting with major bleeding. Clinical hemostasis was assessed by the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria. A total of 29 patients are included in the study. The most common site of bleeding was intracranial hemorrhage (ICH) (72.4%), followed by gastrointestinal bleed (13.8%). Clinical hemostasis was achieved in 21 (72.4%) patients. Patients who did not achieve clinical hemostasis (27.6%) suffered from ICH, and all of them died during hospitalization except for two patients who were discharged with neurologic deterioration. One patient developed multiple brain infarctions after receiving 4-factor PCC. Sixteen patients (55.2%) were receiving concomitant medications that interact with apixaban and rivaroxaban and increase the risk of bleeding. Four-factor PCC appears to be effective in achieving clinical hemostasis in patients on apixaban or rivaroxaban presenting with major bleeding. It may be an alternative to patients who need anticoagulation reversal if the specific antidote, andexanet alfa, is not available.
Asunto(s)
Factores de Coagulación Sanguínea/análisis , Hemorragia/etiología , Pirazoles/efectos adversos , Piridonas/efectos adversos , Rivaroxabán/efectos adversos , Anciano , Anciano de 80 o más Años , Alabama , Coagulación Sanguínea/efectos de los fármacos , Inhibidores del Factor Xa/efectos adversos , Inhibidores del Factor Xa/sangre , Inhibidores del Factor Xa/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridonas/sangre , Piridonas/uso terapéutico , Estudios Retrospectivos , Rivaroxabán/sangre , Rivaroxabán/uso terapéutico , Resultado del TratamientoRESUMEN
Direct oral anticoagulants (DOACs) can be quantified using methods that can be performed in any clinical or research laboratory using manual or automated instrument platforms. Dabigatran etexilate, the oral direct thrombin inhibitor, can be quantified by drug-calibrated clot or chromogenic-based assays using either thrombin or ecarin as substrates. Oral direct anti-Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban, can be quantified with drug-calibrated anti-Xa kits or reagents as typically used for measuring heparins (unfractionated, low molecular weight, or pentasaccharides).
Asunto(s)
Antitrombinas/sangre , Antitrombinas/uso terapéutico , Monitoreo de Drogas/métodos , Inhibidores del Factor Xa/sangre , Inhibidores del Factor Xa/uso terapéutico , Tiempo de Trombina/métodos , Administración Oral , Antitrombinas/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Dabigatrán/administración & dosificación , Dabigatrán/sangre , Dabigatrán/uso terapéutico , Endopeptidasas/administración & dosificación , Endopeptidasas/sangre , Endopeptidasas/uso terapéutico , Inhibidores del Factor Xa/administración & dosificación , Fibrinolíticos/administración & dosificación , Fibrinolíticos/sangre , Fibrinolíticos/uso terapéutico , Humanos , Pirazoles/administración & dosificación , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridinas/administración & dosificación , Piridinas/sangre , Piridinas/uso terapéutico , Piridonas/administración & dosificación , Piridonas/sangre , Piridonas/uso terapéutico , Rivaroxabán/administración & dosificación , Rivaroxabán/sangre , Rivaroxabán/uso terapéutico , Tiazoles/administración & dosificación , Tiazoles/sangre , Tiazoles/uso terapéutico , Tromboembolia Venosa/sangre , Tromboembolia Venosa/tratamiento farmacológicoRESUMEN
BACKGROUND: The use of prothrombin complex concentrates and the role of plasma concentration of anticoagulants in the management of bleeding in patients treated with direct oral anticoagulants are still debated. Our aim was to describe management strategies and outcomes of severe bleeding events in patients treated with direct oral anticoagulants. METHODS: We performed a prospective cohort study of 732 patients treated with dabigatran, rivaroxaban, or apixaban hospitalized for severe bleeding, included prospectively in the registry from June 2013 to November 2015. RESULTS: Bleeding was gastrointestinal or intracranial in 37% (212 of 732) and 24% (141 of 732) of the cases, respectively. Creatinine clearance was lower than 60 ml/min in 61% (449 of 732) of the cases. The plasma concentration of direct oral anticoagulants was determined in 62% (452 of 732) of the cases and was lower than 50 ng/ml or higher than 400 ng/ml in 9.2% (41 of 452) and in 6.6% (30 of 452) of the cases, respectively. Activated or nonactivated prothrombin complex concentrates were administered in 38% of the cases (281 of 732). Mortality by day 30 was 14% (95% CI, 11 to 16). CONCLUSIONS: Management of severe bleeding in patients treated with direct oral anticoagulants appears to be complex. The use of prothrombin complex concentrates differs depending on bleeding sites and direct oral anticoagulant plasma concentrations. Mortality differs according to bleeding sites and was similar to previous estimates.
Asunto(s)
Anticoagulantes/administración & dosificación , Anticoagulantes/sangre , Factores de Coagulación Sanguínea/uso terapéutico , Hemorragia/tratamiento farmacológico , Sistema de Registros , Administración Oral , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Dabigatrán/administración & dosificación , Dabigatrán/sangre , Europa (Continente) , Femenino , Hemorragia/sangre , Humanos , Masculino , Estudios Prospectivos , Pirazoles/administración & dosificación , Pirazoles/sangre , Piridonas/administración & dosificación , Piridonas/sangre , Rivaroxabán/administración & dosificación , Rivaroxabán/sangreRESUMEN
Importance: The non-vitamin K antagonist oral anticoagulants (NOACs) apixaban, dabigatran, edoxaban, and rivaroxaban are administered in fixed doses without anticoagulant monitoring. Randomized trials show that unmonitored NOAC therapy is at least as effective as and safer than dose-adjusted warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Subgroup analyses indicate that plasma drug levels or anticoagulant activity of the NOACs predict stroke and bleeding. This review examines the historical basis for anticoagulant monitoring, discusses methods to measure and interpret drug levels, and critically assesses the role of routine laboratory monitoring in the management of NOAC therapy. Observations: The predictable anticoagulant response of NOACs has provided the pharmacological basis for their administration in fixed doses without routine coagulation monitoring. Although it is possible to accurately measure NOAC drug levels, within-patient variability complicates interpretation of these results. Furthermore, patient characteristics, such as age and renal function, confound the association between NOAC drug levels and clinical outcomes. Information is lacking on the optimal drug level in particular patient groups (eg, elderly, the renally impaired, and those with high bleeding risk), the appropriate dose adjustment to achieve expected levels, and whether routine laboratory monitoring and dose adjustment will improve clinical outcomes. A benefit of a management strategy that incorporates routine therapeutic drug monitoring and dose adjustment over current standard-of-care metrics without such monitoring remains unproven. Conclusions and Relevance: Robust evidence from patients with atrial fibrillation randomized to NOACs or warfarin demonstrates that unmonitored NOAC therapy is at least as effective and safe as monitored warfarin, with lower rates of intracranial hemorrhage and reduced mortality. Further research is required to determine whether routine laboratory monitoring might provide a net benefit for patients. Until such data are available, clinicians should continue to prescribe NOACs in fixed doses without routine monitoring.
Asunto(s)
Fibrilación Atrial/tratamiento farmacológico , Inhibidores del Factor Xa/uso terapéutico , Accidente Cerebrovascular/prevención & control , Anticoagulantes/uso terapéutico , Antitrombinas/sangre , Antitrombinas/uso terapéutico , Fibrilación Atrial/complicaciones , Cromatografía Líquida de Alta Presión , Dabigatrán/sangre , Dabigatrán/uso terapéutico , Inhibidores del Factor Xa/sangre , Hemorragia/inducido químicamente , Humanos , Hemorragias Intracraneales/inducido químicamente , Tiempo de Tromboplastina Parcial , Tiempo de Protrombina , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridinas/sangre , Piridinas/uso terapéutico , Piridonas/sangre , Piridonas/uso terapéutico , Rivaroxabán/sangre , Rivaroxabán/uso terapéutico , Accidente Cerebrovascular/etiología , Espectrometría de Masas en Tándem , Tiazoles/sangre , Tiazoles/uso terapéutico , Tiempo de Trombina , Warfarina/uso terapéuticoRESUMEN
Reliable detection of anticoagulation status in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) is challenging but of importance especially in the emergency setting. This study evaluated the potential of a whole-blood clotting time assay based on Surface Acoustic Waves (SAW-CT) in stroke-patients. The SAW-technology was used for quick and homogenous recalcification of whole blood inducing a surface-activated clotting reaction quantified and visualised by real-time fluorescence microscopy with automatic imaging processing. In 20 stroke or transient ischaemic attack (TIA)-patients taking NOACs kinetics of SAW-CT were assessed and correlated to other coagulation parameters (PT, aPTT) and NOAC-plasma concentration measured by tandem mass spectrometry (LC-MS/MS). In 225 emergency patients with suspicion of acute stroke or TIA, SAW-CT values were assessed. Mean (± SD) SAW-CT in non-anticoagulated stroke patients (n=180) was 124 s (± 21). In patients on dabigatran or rivaroxaban, SAW-CT values were significantly higher 2 and 8 hours (h) after intake rising up to 267 seconds (s) (dabigatran, 2 h after intake) and 250 s (rivaroxaban, 8 h after intake). In patients on apixaban, SAW-CT values were only moderately increased 2 h after intake (SAW-CT 153 s). In emergency patients, SAW-CT values were significantly higher in NOAC and vitamin K antagonist (VKA)-treated as compared to non-anticoagulated patients. In conclusion, the SAW-CT assay is capable to monitor anticoagulant level and effect in patients receiving dabigatran, rivaroxaban and the VKA phenprocoumon. It has a limited sensitivity for apixaban-detection. If specific SAW-CT results were used as cut-offs, SAW-CT yields high diagnostic accuracy to exclude relevant rivaroxaban and dabigatran concentrations in stroke-patients.
Asunto(s)
Anticoagulantes/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Dabigatrán/administración & dosificación , Monitoreo de Drogas/métodos , Ataque Isquémico Transitorio/tratamiento farmacológico , Técnicas Analíticas Microfluídicas , Fenprocumón/administración & dosificación , Pirazoles/administración & dosificación , Piridonas/administración & dosificación , Rivaroxabán/administración & dosificación , Accidente Cerebrovascular/tratamiento farmacológico , Tiempo de Coagulación de la Sangre Total , Administración Oral , Anciano , Anciano de 80 o más Años , Anticoagulantes/efectos adversos , Anticoagulantes/sangre , Automatización de Laboratorios , Cromatografía Líquida de Alta Presión , Dabigatrán/efectos adversos , Dabigatrán/sangre , Femenino , Humanos , Ataque Isquémico Transitorio/sangre , Ataque Isquémico Transitorio/diagnóstico , Masculino , Microscopía Fluorescente , Persona de Mediana Edad , Fenprocumón/efectos adversos , Fenprocumón/sangre , Valor Predictivo de las Pruebas , Pirazoles/efectos adversos , Pirazoles/sangre , Piridonas/efectos adversos , Piridonas/sangre , Reproducibilidad de los Resultados , Rivaroxabán/efectos adversos , Rivaroxabán/sangre , Accidente Cerebrovascular/sangre , Accidente Cerebrovascular/diagnóstico , Espectrometría de Masas en Tándem , Factores de Tiempo , Resultado del TratamientoRESUMEN
Objectives: The three direct oral anticoagulants (DOACs) dabigatran, apixaban and rivaroxaban are now widely used in clinical practice. For patients requiring perioperative interruption of DOACs, heparin bridging is still under discussion. Here we show, for the first time, the influence of concomitantly used DOACs and heparins on laboratory assays. Methods: For spiking experiments, 10 healthy donors and nine patients treated with DOACs were investigated. The measurement of DOACs and heparins was performed with routine methods on the ACL TOP [HEMOCLOT ® direct thrombin inhibitor (CoaChrom Diagnostica, Austria), COAMATIC ® Heparin (Chromogenix, USA) calibrated with rivaroxaban, apixaban, unfractionated heparin (UFH) and low molecular weight heparin (LMWH), additionally PT reagent RecombiPlasTin 2G and aPTT reagent SynthASil (Instrumentation Laboratory, Germany)] and the DOACs were additionally quantified with liquid chromatography-mass spectrometry. A linear regression model has been used to estimate the effect of DOAC prestimulation. Results: No influence of dabigatran could be demonstrated in the anti-Xa testing methods for LMWH, UFH, rivaroxaban or apixaban. All FXa-inhibiting drugs affected all the anti-Xa testing methods in their own specific ways. Compared with heparin alone, measurement of heparins in samples with a basic concentration of DOACs (200 ng/ml) displays a more dramatic increase. Samples of patients with therapeutic intake of DOACs spiked with UFH and LMWH showed the expected pharmacokinetic profiles, but increased pharmacodynamic effects. Conclusions: Direct thrombin and FXa inhibitors exhibit distinct effects on assay results when used concomitantly with heparins. These interactions must be considered in the interpretation of assay results during bridging therapy.
Asunto(s)
Anticoagulantes/administración & dosificación , Heparina/administración & dosificación , Administración Oral , Anticoagulantes/sangre , Anticoagulantes/farmacología , Coagulación Sanguínea/efectos de los fármacos , Pruebas de Coagulación Sanguínea/métodos , Dabigatrán/administración & dosificación , Dabigatrán/sangre , Dabigatrán/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Monitoreo de Drogas/métodos , Inhibidores del Factor Xa/administración & dosificación , Inhibidores del Factor Xa/sangre , Inhibidores del Factor Xa/farmacología , Heparina/sangre , Heparina/farmacología , Heparina de Bajo-Peso-Molecular/administración & dosificación , Heparina de Bajo-Peso-Molecular/sangre , Heparina de Bajo-Peso-Molecular/farmacología , Humanos , Atención Perioperativa/métodos , Pirazoles/administración & dosificación , Pirazoles/sangre , Pirazoles/farmacología , Piridonas/administración & dosificación , Piridonas/sangre , Piridonas/farmacología , Rivaroxabán/administración & dosificación , Rivaroxabán/sangre , Rivaroxabán/farmacologíaRESUMEN
AIM: The present study was to compare the effects of nicotinic acid and nicotinamide on the plasma methyl donors, choline and betaine. METHODS: Thirty adult subjects were randomly divided into three groups of equal size, and orally received purified water (C group), nicotinic acid (300 mg, NA group) or nicotinamide (300 mg, NM group). Plasma nicotinamide, N1-methylnicotinamide, homocysteine, betaine and choline levels before and 1.5-h and 3-h post-dosing, plasma normetanephrine and metanephrine concentrations at 3-h post-dosing, and the urinary excretion of N1-methyl-2-pyridone-5-carboxamide during the test period were examined. RESULTS: The level of 3-h plasma nicotinamide, N1-methylnicotinamide, homocysteine, the urinary excretion of N1-methyl-2-pyridone-5-carboxamide and pulse pressure (PP) in the NM group was 221%, 3972%, 61%, 1728% and 21.2% higher than that of the control group (P < 0.01, except homocysteine and PP P < 0.05), while the 3-h plasma betaine, normetanephrine and metanephrine level in the NM group was 24.4%, 9.4% and 11.7% lower (P < 0.05, except betaine P < 0.01), without significant difference in choline levels. Similar but less pronounced changes were observed in the NA group, with a lower level of 3-h plasma N1-methylnicotinamide (1.90 ± 0.20 µmol/l vs. 3.62 ± 0.27 µmol/l, P < 0.01) and homocysteine (12.85 ± 1.39 µmol/l vs. 18.08 ± 1.02 µmol/l, P < 0.05) but a higher level of betaine (27.44 ± 0.71 µmol/l vs. 23.52 ± 0.61 µmol/l, P < 0.05) than that of the NM group. CONCLUSION: The degradation of nicotinamide consumes more betaine than that of nicotinic acid at identical doses. This difference should be taken into consideration in niacin fortification.
Asunto(s)
Betaína/sangre , Colina/sangre , Niacina/metabolismo , Niacinamida/metabolismo , Adulto , Betaína/metabolismo , Presión Sanguínea , Colina/metabolismo , Suplementos Dietéticos/efectos adversos , Alimentos Fortificados/efectos adversos , Homocisteína/sangre , Homocisteína/metabolismo , Humanos , Hidrólisis , Cinética , Masculino , Metanefrina/sangre , Metanefrina/metabolismo , Metilación , Niacina/efectos adversos , Niacinamida/efectos adversos , Normetanefrina/sangre , Normetanefrina/metabolismo , Piridonas/sangre , Piridonas/metabolismo , Piridonas/orina , Distribución Aleatoria , Adulto JovenRESUMEN
Using functional haemostasis assays, we demonstrated important differences in stability of direct oral anticoagulants (DOACs) in citrated whole blood and plasma from DOAC treated patients. Laboratories and clinicians should take this into consideration and adjust clinical practices accordingly.
Asunto(s)
Anticoagulantes/uso terapéutico , Pruebas de Coagulación Sanguínea , Dabigatrán/uso terapéutico , Monitoreo de Drogas , Pirazoles/uso terapéutico , Piridonas/uso terapéutico , Rivaroxabán/uso terapéutico , Administración Oral , Anticoagulantes/administración & dosificación , Anticoagulantes/sangre , Coagulación Sanguínea/efectos de los fármacos , Pruebas de Coagulación Sanguínea/métodos , Dabigatrán/administración & dosificación , Dabigatrán/sangre , Monitoreo de Drogas/métodos , Estabilidad de Medicamentos , Humanos , Pirazoles/administración & dosificación , Pirazoles/sangre , Piridonas/administración & dosificación , Piridonas/sangre , Rivaroxabán/administración & dosificación , Rivaroxabán/sangreAsunto(s)
Anticoagulantes/sangre , Dabigatrán/sangre , Monitoreo de Drogas/métodos , Pirazoles/sangre , Piridonas/sangre , Rivaroxabán/sangre , Anticoagulantes/efectos adversos , Dabigatrán/efectos adversos , Relación Dosis-Respuesta a Droga , Prescripciones de Medicamentos/estadística & datos numéricos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Hemorragia/inducido químicamente , Humanos , Pirazoles/efectos adversos , Piridonas/efectos adversos , Estándares de Referencia , Factores de Riesgo , Rivaroxabán/efectos adversos , Vitamina K/antagonistas & inhibidoresRESUMEN
Optimization of a benzimidazolone template for potency and physical properties revealed 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as a key template on which to develop a new series of mGlu2 positive allosteric modulators (PAMs). Systematic investigation of aryl-SAR led to the identification of compound 27 as a potent and highly selective mGlu2 PAM with sufficient pharmacokinetics to advance to preclinical models of psychosis. Gratifyingly, compound 27 showed full efficacy in the PCP- and MK-801-induced hyperlocomotion assay in rats at CSF concentrations consistent with mGlu2 PAM potency.
Asunto(s)
Imidazoles/química , Piridinas/química , Piridonas/química , Receptores de Glutamato Metabotrópico/química , Regulación Alostérica , Animales , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Imidazoles/sangre , Imidazoles/farmacología , Imidazoles/uso terapéutico , Locomoción/efectos de los fármacos , Unión Proteica , Trastornos Psicóticos/tratamiento farmacológico , Trastornos Psicóticos/patología , Piridinas/farmacología , Piridinas/uso terapéutico , Piridonas/sangre , Piridonas/farmacología , Ratas , Receptores de Glutamato Metabotrópico/metabolismo , Relación Estructura-ActividadRESUMEN
BACKGROUND AND PURPOSE: Specific coagulation assays for non-vitamin K antagonist oral anticoagulants (NOAC) are relatively slow and often lack availability. Although specific point-of-care tests (POCT) are currently not available, NOAC are known to affect established coagulation POCT. This study aimed at determining the diagnostic accuracy of the CoaguChek POCT to rule out relevant concentrations of rivaroxaban, apixaban, and dabigatran in real-life patients. METHODS: We consecutively enrolled 60 ischemic stroke patients newly started on NOAC treatment and obtained blood samples at 6 prespecified time points. Samples were tested using the CoaguChek POCT, laboratory-based coagulation assays (prothrombin time and activated partial thromboplastin time, anti-Xa test and Hemoclot), and liquid chromatography-tandem mass spectrometry for direct determination of NOAC concentrations. RESULTS: Three hundred fifty-six blood samples were collected. The CoaguChek POCT strongly correlated (r=0.82 P<0.001) with rivaroxaban concentrations but did not accurately detect dabigatran or apixaban. If used to estimate the presence of low rivaroxaban concentrations, POCT was superior to predictions based on normal prothrombin time and activated partial thromboplastin time values even if sensitive reagents were used. POCT-results≤1.0 predicted rivaroxaban concentrations<32 and <100 ng/mL with a specificity of 90% and 96%, respectively. CONCLUSIONS: If anti-Xa test is not available, we propose the use of the CoaguChek POCT to guide thrombolysis decisions after individual risk assessment in rivaroxaban-treated patients having acute ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02371044.
Asunto(s)
Anticoagulantes/uso terapéutico , Inhibidores del Factor Xa/uso terapéutico , Pruebas en el Punto de Atención , Accidente Cerebrovascular/prevención & control , Administración Oral , Anciano , Anticoagulantes/sangre , Dabigatrán/sangre , Dabigatrán/uso terapéutico , Inhibidores del Factor Xa/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridonas/sangre , Piridonas/uso terapéutico , Rivaroxabán/sangre , Rivaroxabán/uso terapéuticoAsunto(s)
Anticoagulantes/uso terapéutico , Monitoreo de Drogas , Farmacovigilancia , Anticoagulantes/efectos adversos , Anticoagulantes/sangre , Bencimidazoles/sangre , Bencimidazoles/uso terapéutico , Dabigatrán , Hemorragia/inducido químicamente , Heparina/efectos adversos , Heparina/sangre , Heparina/uso terapéutico , Humanos , Morfolinas/sangre , Morfolinas/uso terapéutico , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridonas/sangre , Piridonas/uso terapéutico , Rivaroxabán , Tiofenos/sangre , Tiofenos/uso terapéutico , Trombosis/inducido químicamente , Warfarina/efectos adversos , Warfarina/sangre , Warfarina/uso terapéutico , beta-Alanina/análogos & derivados , beta-Alanina/sangre , beta-Alanina/uso terapéuticoRESUMEN
Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for prevention and treatment of thromboembolic diseases. Although routine monitoring will not be required, in certain situations assessment of drug level may be helpful. This study evaluated the suitability of commercially available prothrombin time/international normalised ratio (PT/INR) and anti-FXa activity assays to measure FXa inhibitors in plasma. Twelve PT (ISI 0.89-1.88) and three anti-Xa assays were evaluated in vitro using human plasma spiked with four FXa inhibitors (0-2,000 ng/ml). Assay variability and correlation with drug plasma exposure were evaluated in patients with venous thromboembolism (VTE) treated with apixaban. All FXa inhibitors prolonged PT; however, assay sensitivity was dependent on thromboplastin reagents used and FXa inhibitors tested. To achieve a doubling of PT, the concentration of each FXa inhibitor varied 2.6- to 8-fold between thromboplastin reagents. The rank order of a FXa inhibitor's effect on PT ratio varied across thromboplastin reagents. Conversion to INR increased variability. Different anti-Xa assays showed different dynamic ranges for each FXa inhibitor; however, their rank order was consistent. For apixaban, the dynamic range of <7.8-240 ng/ml, and inter- and intra-assay precision of <6% coefficient of variation by Rotachrom assay appeared suitable for the anticipated apixaban plasma concentrations with 2.5 and 5 mg bid clinical doses. The stronger correlation between apixaban plasma concentration and anti-Xa activity (r2 = 0.88-0.89) compared with PT/INR (r2 = 0.36) in patients undergoing VTE treatment suggested that anti-Xa activity was the better indicator of apixaban plasma concentrations.